Publicacions en què col·labora amb MARIA JESUS SANZ FERRANDO (20)

2023

  1. CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction

    Frontiers in Endocrinology, Vol. 14

  2. Metabolomic signature and molecular profile of normal and degenerated human intervertebral disc cells

    Spine Journal, Vol. 23, Núm. 10, pp. 1549-1562

2022

  1. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?

    Biology, Vol. 11, Núm. 8

  2. Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity

    Microvascular Research, Vol. 139

  3. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players

    Biomedicine and Pharmacotherapy, Vol. 145

  4. Effect of personality on blood glucose control in patients with type 1 diabetes

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 9, pp. 677-685

2021

  1. Activation of the constitutive androstane receptor inhibits leukocyte adhesiveness to dysfunctional endothelium

    International Journal of Molecular Sciences, Vol. 22, Núm. 17

  2. Oral Unsaturated Fat Load Impairs Postprandial Systemic Inflammation in Primary Hypercholesterolemia Patients

    Frontiers in Pharmacology, Vol. 12

  3. Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes

    International Journal of Clinical Practice, Vol. 75, Núm. 8

  4. Postprandial triglyceridaemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects

    International Journal of Clinical Practice, Vol. 75, Núm. 4

  5. The nuclear retinoid‐related orphan receptor RORα controls adipose tissue inflammation in patients with morbid obesity and diabetes

    International Journal of Obesity, Vol. 45, Núm. 7, pp. 1369-1381

2019

  1. Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus

    Translational Research, Vol. 203, pp. 31-48

  2. Novel immune features of the systemic inflammation associated with primary hypercholesterolemia: Changes in cytokine/chemokine profile, increased platelet and leukocyte activation

    Journal of Clinical Medicine, Vol. 8, Núm. 1

  3. SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 39, Núm. 8, pp. 1614-1628

  4. Systemic inflammation in metabolic syndrome: Increased platelet and leukocyte activation, and key role of CX3 CL1/CX3 CR1 and CCL2/CCR2 axes in arterial platelet-proinflammatory monocyte adhesion

    Journal of Clinical Medicine, Vol. 8, Núm. 5

2018

  1. Functional role of endothelial CXCL16/ CXCR6-platelet–leucocyte axis in angiotensin II-associated metabolic disorders

    Cardiovascular Research, Vol. 114, Núm. 13, pp. 1764-1775

  2. Upregulation of angiostatic chemokines IP-10/CXCL10 and I-TAC/CXCL11 in human obesity and their implication for adipose tissue angiogenesis

    International Journal of Obesity, Vol. 42, Núm. 8, pp. 1406-1417

2016

  1. Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/lymphotoxin β-receptor pathway

    Thrombosis and Haemostasis, Vol. 116, Núm. 2, pp. 379-393

2015

  1. Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis

    Journal of Endocrinology, Vol. 227, Núm. 3, pp. 179-191

2014

  1. Insulin resistance aggravates atherosclerosis by reducing vascular smoothmuscle cell survival and increasing CX3CL1/CX3CR1 axis

    Cardiovascular Research, Vol. 103, Núm. 2, pp. 324-336